Novartis-backed GenSight gets cash for gene therapy launch – FierceBiotech
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … |
